|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Segovia-Mendoza M, González-Gonzalez ME,
Barrera D, Díaz L and García-Becerra R: Efficacy and mechanism of
action of the tyrosine kinase inhibitors gefitinib, lapatinib and
neratinib in the treatment of HER2-positive breast cancer:
Preclinical and clinical evidence. Am J Cancer Res. 5:2531–2561.
2015.PubMed/NCBI
|
|
5
|
Das Gupta S, Sae-Tan S, Wahler J, So JY,
Bak MJ, Cheng LC, Lee MJ, Lin Y, Shih WJ, Shull JD, Safe S, et al:
Dietary γ-Tocopherol rich mixture inhibits estrogen-induced mammary
tumorigenesis by modulating estrogen metabolism, antioxidant
response and PPARγ. Cancer Prev Res (Phila). 8:807–816. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thomas C and Gustafsson JA: Estrogen
receptor mutations and functional consequences for breast cancer.
Trends Endocrinol Metab. 26:467–476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu B, Lovre D and Mauvais-Jarvis F: Effect
of selective estrogen receptor modulators on metabolic homeostasis.
Biochimie. 124:92–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Misawa A and Inoue S: Estrogen-related
receptors in breast cancer and prostate cancer. Front Endocrinol
(Lausanne). 6:832015.PubMed/NCBI
|
|
9
|
Xiong R, Patel HK, Gutgesell LM, Zhao J,
Delgado-Rivera L, Pham TN, Zhao H, Carlson K, Martin T,
Katzenellenbogen JA, et al: Selective human estrogen receptor
partial agonists (ShERPAs) for tamoxifen-resistant breast cancer. J
Med Chem. 59:219–237. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaaks R, Lukanova A and Kurzer MS:
Obesity, endogenous hormones, and endometrial cancer risk: A
synthetic review. Cancer Epidemiol Biomarkers Prev. 11:1531–1543.
2002.PubMed/NCBI
|
|
11
|
Fan P, Maximov PY, Curpan RF, Abderrahman
B and Jordan VC: The molecular, cellular and clinical consequences
of targeting the estrogen receptor following estrogen deprivation
therapy. Mol Cell Endocrinol. 418:245–263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boukerroucha M, Josse C, ElGuendi S,
Boujemla B, Frères P, Marée R, Wenric S, Segers K, Collignon J,
Jerusalem G and Bours V: Evaluation of BRCA1-related molecular
features and microRNAs as prognostic factors for triple negative
breast cancers. BMC Cancer. 15:7552015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kehl KL, Shen C, Litton JK, Arun B and
Giordano SH: Rates of BRCA1/2 mutation testing among young
survivors of breast cancer. Breast Cancer Res Treat. 155:165–173.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu J, Li Q, Xu Q, Liu L and Jiang B:
MiR-148a inhibits angiogenesis by targeting ERBB3. J Biomed Res.
25:170–177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aydogdu E, Katchy A, Tsouko E, Lin CY,
Haldosén LA, Helguero L and Williams C: MicroRNA-regulated gene
networks during mammary cell differentiation are associated with
breast cancer. Carcinogenesis. 33:1502–1511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang Q, He M, Ma MT, Wu HZ, Yu ZJ, Guan
S, Jiang LY, Wang Y, Zheng DD, Jin F and Wei MJ: MicroRNA-148a
inhibits breast cancer migration and invasion by directly targeting
WNT-1. Oncol Rep. 35:1425–1432. 2016.PubMed/NCBI
|
|
20
|
Xue J, Chen Z, Gu X, Zhang Y and Zhang W:
MicroRNA-148a inhibits migration of breast cancer cells by
targeting MMP-13. Tumour Biol. 37:1581–1590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Soltani S, Mokarian F and Panjehpour M:
The expression of CK-19 gene in circulating tumor cells of blood
samples of metastatic breast cancer women. Res Pharm Sci.
10:485–496. 2015.PubMed/NCBI
|
|
22
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar
|
|
23
|
Schröder L, Koch J, Mahner S, Kost BP,
Hofmann S, Jeschke U, Haumann J, Schmedt J and Richter DU: The
effects of petroselinum crispum on estrogen receptor-positive
benign and malignant mammary cells (MCF12A/MCF7). Anticancer Res.
37:95–102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murphy E: Estrogen signaling and
cardiovascular disease. Circ Res. 109:687–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matthews J and Gustafsson JA: Estrogen
signaling: A subtle balance between ER alpha and ER beta. Mol
Interv. 3:281–292. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Anbalagan M and Rowan BG: Estrogen
receptor alpha phosphorylation and its functional impact in human
breast cancer. Mol Cell Endocrinol. 418:264–272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bondesson M, Hao R, Lin CY, Williams C and
Gustafsson JÅ: Estrogen receptor signaling during vertebrate
development. Biochim Biophys Acta. 1849:142–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chan S: A review of selective estrogen
receptor modulators in the treatment of breast and endometrial
cancer. Semin Oncol. 29(3 Suppl 11): S129–S133. 2002. View Article : Google Scholar
|
|
29
|
Shang D, Li Z, Zhu Z, Chen H, Zhao L, Wang
X and Chen Y: Baicalein suppresses 17-β-estradiol-induced
migration, adhesion and invasion of breast cancer cells via the G
protein-coupled receptor 30 signaling pathway. Oncol Rep.
33:2077–2085. 2015.PubMed/NCBI
|
|
30
|
Munagala R, Aqil F, Vadhanam MV and Gupta
RC: MicroRNA ‘signature’ during estrogen-mediated mammary
carcinogenesis and its reversal by ellagic acid intervention.
Cancer Lett. 339:175–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vilquin P, Donini CF, Villedieu M, Grisard
E, Corbo L, Bachelot T, Vendrell JA and Cohen PA: MicroRNA-125b
upregulation confers aromatase inhibitor resistance and is a novel
marker of poor prognosis in breast cancer. Breast Cancer Res.
17:132015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yao Y, Hu J, Shen Z, Yao R, Liu S, Li Y,
Cong H, Wang X, Qiu W and Yue L: MiR-200b expression in breast
cancer: A prognostic marker and act on cell proliferation and
apoptosis by targeting Sp1. J Cell Mol Med. 19:760–769. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen Y, Song YX and Wang ZN: The
microRNA-148/152 family: Multi-faceted players. Mol Cancer.
12:432013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takahashi M, Cuatrecasas M, Balaguer F,
Hur K, Toiyama Y, Castells A, Boland CR and Goel A: The clinical
significance of MiR-148a as a predictive biomarker in patients with
advanced colorectal cancer. PLoS One. 7:e466842012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xia J, Guo X, Yan J and Deng K: The role
of miR-148a in gastric cancer. J Cancer Res Clin Oncol.
140:1451–1456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li J, Song Y, Wang Y, Luo J and Yu W:
MicroRNA-148a suppresses epithelial-to-mesenchymal transition by
targeting ROCK1 in non-small cell lung cancer cells. Mol Cell
Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
